President Donald Trump's healthcare proposal, first described as "concepts" during a debate in 2026, continues to be a work in progress, with critics characterizing the "Great Healthcare Plan" as vague and lacking in specifics regarding its funding and implementation.
The administration released a legislative framework for the plan in January 2026, aiming to address prescription drug costs, reduce insurance premiums, and increase transparency in the healthcare sector. However, the outline provided little detail on how these provisions would be funded or enacted, and it would require congressional approval.
At the time of its release, news outlets described the plan as "sparse on details." Trump has recently highlighted the proposal as a response to soaring healthcare costs, a key concern for voters ahead of midterm elections. This comes after Affordable Care Act premiums surged for many Americans when enhanced subsidies were not extended by the Republican-controlled Congress, and as previous actions under Trump's administration, such as potential Medicaid cuts and work requirements, were projected to put millions at risk of losing coverage.
During a recent Republican midterm convention, Trump stated, "We will pass the Great Healthcare Plan to stop all government payments to big insurance companies, and give the money directly to the people, for you to buy your own healthcare and have money left over." This approach aligns with Republican proposals to deposit funds directly into individuals' Health Savings Accounts (HSAs). However, critics argue that these accounts have limitations on fund usage, are often paired with costly high-deductible plans, and the proposed deposit amounts may be insufficient to cover potential premium increases.
During his presidency, Trump pursued healthcare initiatives through executive actions. One order in 2025 aimed to align U.S. drug prices with those in comparable countries via "most favored nation" prescription drug pricing. While the White House announced deals with pharmaceutical companies, few details have been disclosed. Additionally, the TrumpRx website, intended to connect consumers with prescription drug deals, has been criticized for offering a limited selection of medications and lacking information on cheaper generic alternatives.
More recently, Trump pledged $500 rebate checks to about one million Obamacare enrollees, a move that critics argue is insufficient to offset the significant cost increases many individuals are experiencing due to the lapse of tax credits.
The White House did not immediately respond to requests for comment.